Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Cyrus Taraporevala is Director at Pfizer. OQRO lists 5 transactions filed with the SEC under this name, the latest on Sep 29, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
PfizerPFE
5 disclosures · Jan 2026 – Sep 2026
Sep 25, 20261,307.99disclosed Sep 29
DetailsOfficial recordJun 26, 20261,543.85disclosed Jun 30
DetailsOfficial recordApr 23, 20267,686.54disclosed Apr 27
DetailsOfficial recordMar 27, 20261,386.83disclosed Mar 31
DetailsOfficial recordDec 31, 20251,506.02disclosed Jan 5
DetailsOfficial recordCyrus Taraporevala has no open-market purchase on record since 2021. Sales in 1 of the 6 years since 2021.
Cyrus Taraporevala reported 0 open-market purchases and 6 sales since 2021; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $2.42M6×6 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Cyrus Taraporevala has no open-market purchase on record since 2021. Sales in 1 of the 6 years since 2021.
In SEC filings since 2021: no open-market purchase is on record; the latest open-market sale is from 2021.
State Street Corporation (STT), from 2021 to 2021: 0 purchases and 6 sales.
Cyrus Taraporevala reported 0 open-market purchases and 6 sales here, 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.